Friday, July 26, 2013

Takeda gets EU CHMP nod for Alogliptin and fixed dose combination of Alogliptin with metformin and pioglitazone

The EU CHMP recommended approval for Alogliptin (Vipidia) and two other medicines comprising alogliptin  as one of the component (Incresync and Vipdomet).  Incresync is a fixed dose combination of Alogliptin and pioglitazone, while Vipdomet is an FDC of alogliptin and metformin.
If approved, Alogliptin would be the fifth DPP-IV  on the market. Other DPP-IV approved in Europe include saxagliptin, sitagliptin, vildagliptin and linagliptin.

The approval also come along with a positive review by EMA on the safety of DPP-IV's and GLP-1 agonist.




Enter your email address:


Delivered by FeedBurner